Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Chatelut

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2007
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendationsV Launay-Vacher, E Chatelut, S M Lichtman, et al.
Clinical Neuropharmacology|December 1, 1990
Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatmentG Durrieu, Y Rispail, E Chatelut, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26)P Canal, R Bugat, E Chatelut, et al.
Archives of Neurology|March 1, 1993
Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I studyM C Chamberlain, S Khatibi, J C Kim, et al.
British Journal of Cancer|June 28, 2007
Clinical pharmacodynamic factors in docetaxel toxicityF Puisset, J Alexandre, J-M Treluyer, et al.
Bulletin Du Cancer|July 1, 1997
[Bayesian estimation of pharmacokinetic parameters of etoposide]E Evene, E Chatelut, B Tranchand, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 1998
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysisM C Etienne, E Chatelut, X Pivot, et al.
Acta Medica Austriaca|January 1, 1989
Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfateP Canal, M de Forni, E Chatelut, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
A limited sampling strategy for determining carboplatin AUC and monitoring drug dosageE Chatelut, X Pivot, J Otto, et al.
British Journal of Cancer|August 30, 2012
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsE Chatelut, M L White-Koning, R Hj Mathijssen, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2007
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendationsV Launay-Vacher, E Chatelut, S M Lichtman, et al.
Clinical Neuropharmacology|December 1, 1990
Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatmentG Durrieu, Y Rispail, E Chatelut, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1989
Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26)P Canal, R Bugat, E Chatelut, et al.
Archives of Neurology|March 1, 1993
Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I studyM C Chamberlain, S Khatibi, J C Kim, et al.
British Journal of Cancer|June 28, 2007
Clinical pharmacodynamic factors in docetaxel toxicityF Puisset, J Alexandre, J-M Treluyer, et al.
Bulletin Du Cancer|July 1, 1997
[Bayesian estimation of pharmacokinetic parameters of etoposide]E Evene, E Chatelut, B Tranchand, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 1998
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysisM C Etienne, E Chatelut, X Pivot, et al.
Acta Medica Austriaca|January 1, 1989
Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfateP Canal, M de Forni, E Chatelut, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
A limited sampling strategy for determining carboplatin AUC and monitoring drug dosageE Chatelut, X Pivot, J Otto, et al.
British Journal of Cancer|August 30, 2012
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsE Chatelut, M L White-Koning, R Hj Mathijssen, et al.
Pageof 8